Day: January 7, 2024

ALISO VIEJO, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2023 ResultsPreliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million, representing growth of approximately 78% compared to the prior year period, driven by:The sale of 77 Light Delivery Devices (LDD™s), expanding the installed base to 666 LDDs as of December 31, 2023; and The sale of 18,071 Light Adjustable Lenses (LAL®s).Preliminary unaudited 2023 fiscal year revenue is expected...

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*. Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences. Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and...

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited.Revenue for the fourth quarter of 2023 is expected to be between $25.5 million and $26.5 million, as compared to $21.2 million for the corresponding quarter of 2022. For the fiscal year of 2023, revenue is expected to be between $95.6 million and $96.6 million, as compared to $74.9 million for the fiscal year of 2022. Year end 2023 projected cash, cash equivalents, and restricted cash balance is expected to be between $83.0 million...

Gentex’s eSight GoeSight is a wearable assistive technology that allows people living with visual impairments to stay on the go while performing the tasks of daily living. The comprehensive medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision.Gentex’s eSight GoeSight eyewear combines a high-definition camera, proprietary algorithms, and powerful processing platform to relay and magnify real-time imagery onto two high-resolution screens positioned before each eye, resulting in enhanced binocular vision.LAS VEGAS, Jan. 07, 2024 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX) announced today the asset acquisition of eSight, a leading provider of vision enhancement technologies, to develop and manufacture the next...

The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to market the combination of Akoya’s spatial biology solutions, including its PhenoImager® systems and PhenoCode™ reagents with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples. The agreement facilitates a streamlined workflow for whole-slide, multiomic imaging, where protein and RNA biomarkers play complementary roles...